Most Recent
Regeneron, Bayer take fight over Eylea biosimilar to appeals court
Intellectual Property 2025-09-17 11:50 pm By Christine Caulfield

Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Regeneron, Bayer lose bid to block Sandoz from launching Eylea biosimilar
Intellectual Property 2025-09-08 11:55 pm By Cindy Cameronne

Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Court rejects ‘entirely unwarranted’ attack on Allens solicitors in fight over lift IP
Intellectual Property 2025-08-22 11:10 pm By Sam Matthews

A court has dismissed a lift supplier’s appeal of a decision rejecting its claim of breach of confidence against a rival, including an “entirely unwarranted” attack on solicitors at Allens over the use of documents obtained by “internet-savvy” search techniques.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pilatus wins discovery for potential IP suit linked to Air Force contract
Intellectual Property 2025-01-21 11:21 pm By Andy Sidler

Swiss aircraft manufacturer Pilatus has won discovery to pursue a possible copyright claim stemming from a Royal Australian Air Force flight simulator contract.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Neurim’s claim for additional damages survives in Circadin patent case
Intellectual Property 2024-06-03 11:48 pm By Sam Matthews

A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company’s failure to comply with an earlier ruling.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

After 7 years of litigation, patent for blockbuster sleep drug Circadin found valid
Intellectual Property 2024-04-18 11:21 pm By Sam Matthews

After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceutical’s patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Crypto gambling site Stake.com fights TM suit over Aussie launch
Intellectual Property 2023-10-04 2:02 pm By Cindy Cameronne

Global cryptocurrency and gambling website Stake.com is fighting to strike out claims in a lawsuit by Sydney-based online investment platform Stake over a planned Australian launch.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

High Court won’t step in to revive Energy Beverages’ ‘Motherland’ trade mark
Intellectual Property 2023-09-18 11:11 pm By Cat Fredenburgh

The maker of Mother Energy drinks has failed to convince the High Court that it should weigh in on its long-running intellectual property spat with Vittoria Coffee, which ended in the removal of its ‘Motherland’ trade mark.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Lights out on Hanhwa’s solar cell patent infringement suit
Intellectual Property 2023-09-01 11:57 pm By Christine Caulfield

A solar cell patent at the heart of intellectual property litigation brought by South Korean technology giant Hanwha has been found invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Optus to rebrand ‘Boost’ products in trade mark case settlement
Telecommunications 2023-06-14 4:46 pm By Christine Caulfield

Optus has agreed to rebrand products that Boost Tel claimed had infringed on its trade marks, in  a settlement of the rivals’ intellectual property spat.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?